Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06503107
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-06-17
Brief Title:
Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of RRMM
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Multicenter Clinical Study on the Safety and Efficacy of Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of RelapsedRefractory Multiple Myeloma
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To explore the safety and efficacy of nanobody-based BCMA-targeting biepitope CAR-T cells in the treatment of relapsedrefractory multiple myelomathis study will be conducted in multiple study centers with 60 patients openly enrolled to receive CAR-T cell therapy Patients participating in clinical trials will be tested and evaluated for treatment safety efficacy duration of response and long-term survival
Detailed Description:
This study is a multicenter open-label prospective single-arm clinical study with patients with relapsedrefractory multiple myeloma as the test subjects in order to evaluate the safety and efficacy of nanobody-based biepitope CAR-T cells targeting BCMA in the treatment of RRMM and to collect CAR-T PKPD indicators The structure of BCMA target CAR-T is designed to identify two different epitopes of BCMA protein with two recognition domains in order to killig MM cells without secreting more pro-inflammatory factors and avoiding escape caused by the limitations of single BCMA antigen recognition
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None